B+
Bull case
25%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
LEGN
Legend BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 release materially improved operating evidence: CARVYKTI sales grew 50% year over year, profitability improved, access expanded, and LB2501 produced an early clinical proof-of-concept. The balance-sheet raise also extends financing flexibility.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.4.
What can break
CARVYKTI concentration and dependence on continued commercial execution with Johnson & Johnson.
Momentum
12
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $26.00 · Bull $38.00 · Bear $15.00Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $47.15
Why
Momentum12 · Δ7d +6.7
Value41 · Δ7d 0.0
Sentiment100 · Δ7d +11.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +11.4.
Contradictions & invalidation
- • CARVYKTI concentration and dependence on continued commercial execution with Johnson & Johnson.
- • LB2102 remains a Phase 1 program with early clinical data and development risk.
- • The pipeline evidence is early, cash flow remained negative in the quarter, the company raised capital through a 7.7 million ADS offering, and the business remains highly dependent on CARVYKTI execution and the Janssen collaboration.
Catalyst clock
2026-08-11
Q2 2026 showed commercial growth and first reported operating profit
Lead driver: Sentiment · See AI snapshot
Momentum
12
9% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
+9.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+11.4
Δ21d
+11.1
Why this grade
Composite grade A. Momentum 12.5 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4B
Beta
0.11
Shares Out
193.77M
P/E (TTM) · Derived
-12.8
P/S (TTM)
4.13
P/FCF (TTM) · Derived
-14.57
Rev YoY
+51.6%
EPS YoY
-126.0%
Gross Margin
+53.0%
Op Margin
-4.1%
Net Debt
-$534.9M
Current Ratio
3.04
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data